

#### Growth of high-cell density microbial cultures in a single-use fermentor system

Intellectual Property Notice: The Biopharma business of GE Healthcare was acquired by Danaher on 31 March 2020 and now operates under the Cytiva<sup>™</sup> brand. Certain collateral materials (such as application notes, scientific posters, and white papers) were created prior to the Danaher acquisition and contain various GE owned trademarks and font designs. In order to maintain the familiarity of those materials for long-serving customers and to preserve the integrity of those scientific documents, those GE owned trademarks and font designs remain in place, it being specifically acknowledged by Danaher and the Cytiva business that GE owns such GE trademarks and font designs.

#### cytiva.com

GE and the GE Monogram are trademarks of General Electric Company.

Other trademarks listed as being owned by General Electric Company contained in materials that pre-date the Danaher acquisition and relate to products within Cytiva's portfolio are now trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. All other third-party trademarks are the property of their respective owners. © 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit <a href="https://contact.com/contact">cytiva.com/contact</a>

CY13622-21May20-PT



# Growth of high-cell density microbial cultures in a single-use fermentor system

Jinghui Xu<sup>1</sup>, Patrick Guertin<sup>2</sup>, and Parrish Galliher<sup>2</sup>

<sup>1</sup>GE Healthcare Life Sciences, Shanghai, China. <sup>2</sup>GE Healthcare Life Sciences, Marlborough, USA.

Abstract

Introduction

Cell growth and production in E. coli fed-batch cultures

Here we show the performance of a single-use Xcellerex™ XDR-50 MO fermentor system when used in high-cell density cultivations of *E. coli* producing a domain antibody (Dab) and of modified *Pseudomonas* fluorecsens (P. fluorescens) producing a monoclonal antibody (MAb) (Fig 1). Both the achieved microbe densities and product yield were shown to be consistent with the performance of conventional stainless steel and glass bioreactor systems.



Fig 1. XDR-50 MO fermentor system.

Microbial processes are widely used for industrial production of biopharmaceuticals. Due to the historical limitations of single-use technologies, biomanufacturers have traditionally been referred to the use of stainless steel equipment for these processes. Bioreactors designed for mammalian processes fall short of meeting the unique requirements of production in microbial processes in terms of, for example, oxygen transfer capacity and temperature control. Xcellerex XDR-50 MO fermentor system is purpose-designed and built to overcome the mammalian single-use system limitations in fulfilling the needs of a microbial process. The culture vessel features a dimpled jacket heat transfer surface for efficient cooling and heating of the culture. Robust agitation is provided by a powerful magnetic drive and a two-stage impeller, resulting in a high oxygen transfer to the culture medium.

A domain antibody (Dab) was produced in parallel fed-batch cultures of *E. coli* using XDR-50 fermentor and a reference stainless steel system from Belach Bioteknik AB. Microbial growth achieved in XDR-50 MO fermentor was comparable with that of the reference bioreactor (Fig 7). Product titers were also similar between the systems: 2 g/L for XDR-50 MO and 2.2 g/L for the reference bioreactor.





Fig 7. Cell growth in a 30 L XDR-50 MO fermentor culture versus in a 10 L culture in the reference stainless steel bioreactor.

#### **XDR-50 MO design features**

As shown in Figures 2 and 3, baffle geometry and agitation rate have significant impact on oxygen transfer rate (OTR). As indicated in Figure 4, working volume has inverse impact on OTR. Oxygen content has highest impact on OTR (Fig 5), whereas when flow rate is above



 $(35 L, 350 rpm, 50\% air, 50\% O_2, 32'' \times 1.25'' baffles).$ 

## Cell growth and production in P. fluorescens fed-batch cultures

A monoclonal antibody (MAb) was produced in parallel fedbatch cultures of *P. fluorescens* using XDR-50 fermentor and a reference glass bioreactor from New Brunswick Scientific. The final OD<sub>575</sub> of the cultures ranged from 193 to 375 and the MAb yields from 46 to 72 mg/L. Both the achieved culture densities and MAb yields are consistent between the systems (data not shown). Figure 8 displays two parallel runs in the XDR-50 fermentor, exhibiting high cell growth.




Fig 8. Cell growth in two parallel 30 L XDR-50 MO fermentor cultures.

#### Discussion

1 VVM, 32'' × 1.25'' barffles).

The fermentor is designed to meet the unique requirements of microbial cultures in terms of, for example, high oxygen transfer capacity and high cooling capacity. As shown in applications with E. coli and P. fluorescens, the XDR-50 MO fermentor is capable of delivering both cell growth and protein production equivalent to those of conventional stainless steel and glass microbial fermentor systems. The improved features and benefits of this single-use system eliminates the need for time-consuming cleaning-inplace and sterilization-in-place operations and offers increased operational flexibility for the biomanufacturer using microbial processes.

## Conclusions

- The single-use Xcellerex XDR-50 MO supports cell growth comparable with conventional fermentor systems
- A system design with a powerful drive enables high oxygen transfer rates > 500 mmole  $L^{-1} h^{-1}$
- The XDR-50 MO cooling capacity is sufficient to support high-density microbial cultures

GE and GE monogram are trademarks of General Electric Company. Xcellerex is a trademark of General Electric Company or one of its subsidiaries. © 2014 General Electric Company – All rights reserved. First published Oct. 2014. All goods and services are sold subject to terms and conditions of sale of the GE Healthcare Company which supplies them. A copy of these terms and conditions are available on request. Contact your GE Healthcare representative for the most current information and a copy of the terms and conditions. GE Healthcare Bio-Sciences AB, Björkgatan 30, 751 84 Uppsala, Sweden.